Multidrug Resistance 1 Gene Expression and AgNOR in Childhood Acute Leukemias

Overview

Journal Indian J Hematol Blood Transfus

Specialty Hematology

Date 2012 Oct 27

PMID 23100919

Citations 1

Authors

S Balamurugan

D Sugapriya

P Shanthi

V Thilaka

S Venkatadesilalu

V Pushpa

M Madhavan

Affiliations

Soon will be listed here.

Abstract

The multidrug resistance 1 (MDR1) gene product, P-glycoprotein (Pgp/p170) is a membrane protein, which acts as an ATP dependant efflux pump that expels a wide variety of organic compounds including chemotherapeutic agents from the cell. Pgp over expression has been demonstrated to be linked with poor treatment outcome and poor prognosis in a number of malignant tumors. AgNORs is a simple, reliable and inexpensive method of evaluating the proliferative activity of a tumor. We have studied MDR1 expression and AgNORS in 41 cases of acute leukemia in children. In this study, AgNOR counts in patients with acute lymphoblastic leukemia (ALL) L2 subtype (FAB classification) were significantly higher as compared to the ALL L1 subtype. Similarly, mean AgNOR count in the acute myeloid Leukemia (AML) M2 subtype was significantly higher as compared to the ALL L1 subtype. However, there was no correlation between AgNOR and treatment outcome or between AgNOR counts and MDR1 expression in any of the subtypes of acute leukemia included in this series. In AML, MDR1 gene expression was found to be related to reduced remission induction rates and hence poorer prognosis. In ALL, our study has shown no difference in remission induction between MDR1 positive and MDR1 negative cases. This would suggest that factors other than MDR1 may be of relevance in Pediatric ALL.

Citing Articles

Variants in TPMT, ITPA, ABCC4 and ABCB1 Genes As Predictors of 6-mercaptopurine Induced Toxicity in Children with Acute Lymphoblastic Leukemia.

Milosevic G, Kotur N, Krstovski N, Lazic J, Zukic B, Stankovic B J Med Biochem. 2019; 37(3):320-327.

PMID: 30598629 PMC: 6298470. DOI: 10.1515/jomb-2017-0060.

References

Casale F, DAngelo V, Addeo R, Caraglia M, Crisci S, Rondelli R . P-glycoprotein 170 expression and function as an adverse independent prognostic factor in childhood acute lymphoblastic leukemia. Oncol Rep. 2004; 12(6):1201-7. DOI: 10.3892/or.12.6.1201. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . Proposals for the classification of the acute leukaemias. French-American-British (FAB) co-operative group. Br J Haematol. 1976; 33(4):451-8. DOI: 10.1111/j.1365-2141.1976.tb03563.x. View

Solary E, Drenou B, Campos L, de Cremoux P, Mugneret F, Moreau P . Quinine as a multidrug resistance inhibitor: a phase 3 multicentric randomized study in adult de novo acute myelogenous leukemia. Blood. 2003; 102(4):1202-10. DOI: 10.1182/blood-2002-11-3419. View

Haber D . Multidrug resistance (MDR 1) in leukemia: is it time to test?. Blood. 1992; 79(2):295-8. View

Goasguen J, Dossot J, Fardel O, Le Mee F, Le Gall E, Leblay R . Expression of the multidrug resistance-associated P-glycoprotein (P-170) in 59 cases of de novo acute lymphoblastic leukemia: prognostic implications. Blood. 1993; 81(9):2394-8. View

Asakura K, Uchida H, Miyachi H, Kobayashi H, Miyakawa Y, Nimer S . TEL/AML1 overcomes drug resistance through transcriptional repression of multidrug resistance-1 gene expression. Mol Cancer Res. 2004; 2(6):339-47. View

Baccarani M, Damiani D, Michelutti A, Michieli M . Expression of multidrug resistance gene (MDR1) in normal hematopoietic cells. Blood. 1993; 81(12):3480-1. View

Bennett J, Catovsky D, Daniel M, Flandrin G, GALTON D, Gralnick H . The morphological classification of acute lymphoblastic leukaemia: concordance among observers and clinical correlations. Br J Haematol. 1981; 47(4):553-61. DOI: 10.1111/j.1365-2141.1981.tb02684.x. View

Crocker J, Boldy D, Egan M . How should we count AgNORS? Proposals for a standardized approach. J Pathol. 1989; 158(3):185-8. DOI: 10.1002/path.1711580303. View

10.

Sreelekha T, Kusumakumary P, Srinivas G, Kumar S, Pushpakumary S, Nair M . Argyrophilic nuclear organizer regions (AgNORs) in pediatric acute lymphoblastic leukemia. Cancer Lett. 1996; 108(1):87-91. DOI: 10.1016/s0304-3835(96)04397-2. View

11.

Dhooge C, De Moerloose B, Laureys G, Ferster A, De Bacquer D, Philippe J . Expression of the multidrug transporter P-glycoprotein is highly correlated with clinical outcome in childhood acute lymphoblastic leukemia: results of a long-term prospective study. Leuk Lymphoma. 2002; 43(2):309-14. DOI: 10.1080/10428190290006080. View

12.

Filipits M, Suchomel R, Lechner K, Pirker R . Immunocytochemical detection of the multidrug resistance-associated protein and P-glycoprotein in acute myeloid leukemia: impact of antibodies, sample source and disease status. Leukemia. 1997; 11(7):1073-7. DOI: 10.1038/sj.leu.2400655. View

13.

Musto P, Melillo L, Lombardi G, Matera R, Di Giorgio G, Carotenuto M . High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P-glycoprotein positive cells in complete remission. Br J Haematol. 1991; 77(1):50-3. DOI: 10.1111/j.1365-2141.1991.tb07947.x. View

14.

Ross D . Modulation of drug resistance transporters as a strategy for treating myelodysplastic syndrome. Best Pract Res Clin Haematol. 2004; 17(4):641-51. DOI: 10.1016/j.beha.2004.08.014. View

15.

Campos L, Guyotat D, Archimbaud E, Tsuruo T, Troncy J, Treille D . Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood. 1992; 79(2):473-6. View

16.

Flens M, Zaman G, van der Valk P, Izquierdo M, Schroeijers A, Scheffer G . Tissue distribution of the multidrug resistance protein. Am J Pathol. 1996; 148(4):1237-47. PMC: 1861521. View

17.

MacFarland A, Dawson A, Pearson C . Analysis of MDR1 and MDR3 multidrug resistance gene expression and amplification in consecutive samples in patients with acute leukaemias. Leuk Lymphoma. 1995; 19(1-2):135-40. DOI: 10.3109/10428199509059667. View

18.

Pich A, Chiusa L, Audisio E, Marmont F . Nucleolar organizer region counts predict complete remission, remission duration, and survival in adult acute myelogenous leukemia patients. J Clin Oncol. 1998; 16(4):1512-8. DOI: 10.1200/JCO.1998.16.4.1512. View

19.

Shome D, Khurana N . Distinctive AgNOR patterns of myeloid and lymphoid blasts in acute leukemia. Am J Hematol. 1999; 61(2):149-52. DOI: 10.1002/(sici)1096-8652(199906)61:2<149::aid-ajh14>3.0.co;2-z. View